Top-News
Dienstag, 10.09.2024 17:45
von
GlobeNewswire
| Aufrufe: 195
Global Bioenergies: net loss reduced to €2.8m in first-half 2024
Zeitungsständer (Symbolbild).
© AdrianHancu / iStock Editorial / Getty Images Plus / Getty Images
PRESS RELEASE
Global Bioenergies: net loss reduced to €2.8m
in first-half 2024
Net loss reduced to -2.8 M€ compared to -€4.1 million in H1 2023
and -€5.8 million for H1 2022
Gross cash position of €7.7 million as of 30 June 2024
vs €11.7 million as of 31 December 2023
Evry, 10 September 2024 – 05:45 p.m.: Global Bioenergies' Board of Directors today approved the financial statements for the first half of 2024, which have been audited by the Statutory Auditor.
Samuel Dubruque, Chief Financial Officer, comments: « Our result is improved compared to previous years: the half-year loss is limited to €2.8 million, due in particular to the recording of an operating subsidy for the Isoprod program financed by ADEME. We started the year with a gross cash position of €11.7 million, and had a cash position of €7.7 million at 30 June 2024. The first half of the year saw us consolidate our plant project: improvements in process performance at pilot scale, receipt of letters of intent exceeding the plant's production capacity, completion of the basic engineering and pre-selection of the site in France. One year ago we obtained the support of the French government with a €16.4 million grant from Bpifrance. Since then, we have been striving to find additional debt and equity investors in a particularly adverse climate due to the political and economic uncertainties that are complicating the project’s completion. In this context, we are nevertheless pleased to announce that we have passed the first selection stage of a European financing package worth a total of €17.5 million for the financing of this plant, the final result of which is expected in H1 2025”.
Marc Delcourt, Co-founder and CEO, adds: “The progress made in our cosmetics plant project translate directly into the strategic field of SAF (Sustainable Aviation Fuels). Improved performance and the identification of a new resource, acetic acid, open the door to the production of e-SAF via our process, and reaffirm Global Bioenergies' potential to become a key player in this field of aviation, which is currently in search of solutions.”
Group Profit & Loss Account
| € thousands | from 01/01/24 to 30/06/24 6 months | from 01/01/23 to 30/06/23 6 months | from 01/01/22 to 30/06/22 6 months |
| Operating income | 4.612 | 7,326 | 1,059 |
| Operating expenses | 7,504 | 11,264 | 6,632 |
| Operating profit (loss) | -2,892 | -3,938 | -5,573 |
| EBITDA1 | -976 | -3,026 | -5,024 |
| Financial profit (loss) | 144 | 23 | -61 |
| Exceptional profit (loss) | -42 | -169 | -124 |
| Income tax | NA | NA | NA |
| Net profit (loss) | -2,789 | -4,084 | -5,759 |
Anzeige
Aktie im Fokus
|
Purewave Hydrogen Corp
0,25
€
+13,3%  |
Die nächste große Aktienchance kommt aus den USA!
Kurse
 |
| € thousand | from 01/01/24 to 30/06/2024 6 months | from 01/01/23 to 30/06/2023 6 months | from 01/01/22 to 30/06/2022 6 months |
| Operating income | 4,612 | 7,326 | 1,059 |
| Revenue | 339 | 3,102 | 144 |
| Operating subsidies | 4,091 | 1,184 | 894 |
| Change in the inventory of finished products | -263 | 1,917 | -34 |
| Other income | 445 | 1,123 | 55 |
Operating income includes recognition of subsidy income from two projects supported by ADEME: the end of the Isoprod project validating isobutene derivatives in cosmetics, and subsidy income from the ongoing Prénidem project.
| € thousand | from 01/01/24 to 30/06/2024 6 months | from 01/01/23 to 30/06/2023 6 months | from 01/01/22 to 30/06/2022 6 months |
| Operating expenses | 7,504 | 11,264 | 6,632 |
| Staff costs | 2 231 | 2 194 | 2 309 |
| Average number of employees (No.) | 45.2 | 47.6 | 47.3 |
| Industrialisation expenses | 1,191 | 2,687 | 2,597 |
| Change in IBN and derivatives inventories | -97 | 2,461 | -584 |
| Laboratory costs | 170 | 192 | 185 |
| Rent, servicing & maintenance | 536 | 518 | 423 |
| Intellectual property | 178 | 186 | 137 |
| Depreciation, amortisation and provisions | 2,361 | 2,028 | 559 |
| Other structural costs | 934 | 997 | 1,006 |
The industrialisation expenses were mainly used to demonstrate the success of the process scale-up within at our ARD-operated facilities in Pomacle-Bazancourt.
Group Balance Sheet
| Assets (€ thousand) | 30/06/24 | 31/12/23 | 31/12/22 | Liabilities (€ thousand) | 30/06/24 | 31/12/23 | 31/12/22 | |
| Intangible assets | 204 | 327 | 539 | Capital | 908 | 906 | 749 | |
| Tangible assets | 647 | 2,471 | 3,612 | Share premium | 10,538 | 16,029 | ||
| Assets under construction | 394 | 77 | 401 | Balance carried forward | -940 | -2,769 | -2,708 | |
| Financial assets | 347 | 341 | 1,546 | Profit (loss) | -2,789 | -8,656 | -11,986 | |
| Equipment subsidies | 2 675 | 2 758 | 463 | |||||
| NON CURRENT ASSETS | 1,591 | 3,217 | 6,097 | EQUITY | -146 | 2,778 | 2,547 | |
| IBN and derivatives inventories | 209 | 219 | 2,342 | PROVISIONS | 210 | 53 | 110 | |
| Consumables inventories | 372 | 350 | 250 | |||||
| Receivables | 3,338 | 2,247 | 3,647 | Conditional advances and loans | 10,443 | 12,451 | 11,486 | |
| Cash | 7,515 | 11,673 | 8,768 | Trade payables | 2,507 | 2,411 | 5,580 | |
| Marketable securities | 171 | 171 | 173 | Tax and social securities liabilities | 625 | 559 | 502 | |
| Prepaid expenses | 451 | 378 | 300 | Other debts and deferred income | 8 | 3 | 1,352 | |
| CURRENT ASSETS | 12,055 | 15,038 | 15,480 | PAYABLES | 13,583 | 15,423 | 18,921 | |
| TOTAL ASSETS | 13,647 | 18,254 | 21,577 | TOTAL LIABILITIES | 13,647 | 18,254 | 21,577 |
Gross cash flow amounts to €7.7 million as of 30 June 2024, compared to €11.7 million as of 31 December 2023.
Highlights of the first half of 2024, recent events and outlook
- Technical and commercial progress in the cosmetics plant project
The first half of the year was marked by progress made on the technical and commercial aspects of the project to build a plant with a capacity of 2,500 tonnes/year to address the cosmetics markets. On the technical side, scale-up tests demonstrated that performance would hold up well in larger fermenters, thus confirming the assumptions made in the plant's business plan. The preliminary design, which was successfully completed, confirmed the nominal CAPEX of €65 million (i.e. a maximum CAPEX of around €80 million taking contingencies into account). On the commercial side, potential customers showed their interest with letters of intent from several geographies, far exceeding the plant's production capacity.
- Development of the technological process for e-SAF production
Global Bioenergies has successfully extended its bio-SAF production process to the production of e-SAF in the laboratory by replacing plant resources with a synthetic resource, acetic acid. This e-SAF approach stands out for its selectivity of over 95%, meaning that more than 95% of the molecules resulting from the process can be marketed as jet fuel. This selectivity exceeds that of other existing e-SAF technologies.
As a reminder, e-SAFs, produced solely from CO2 and renewable electricity, maximize the decarbonisation potential of SAF. Bio-SAF and e-SAF are regulated by the European Union's ReFuelEU Aviation regulation, which imposes dedicated mandates for these two fuels. By 2030, all aircraft taking off from the European Union must carry at least 4.8% bio-SAF and 1.2% e-SAF in their fuel tanks.
About GLOBAL BIOENERGIES
As a committed player in the fight against global warming, Global Bioenergies has developed a unique process to produce SAF and e-SAF from renewable resources, thereby meeting the challenges of decarbonising air transport. Its technology is one of the very few solutions already certified by ASTM. Its products also meet the high standards of the cosmetics industry, and L'Oréal is its largest shareholder with a 13.5% stake. Global Bioenergies is listed on Euronext Growth in Paris (FR0011052257 - ALGBE).
Contacts
| GLOBAL BIOENERGIES +33 (0)1 64 98 20 50 invest@global-bioenergies.com Follow our news Receive information about Global Bioenergies directly by subscribing to our news feed on https://www.global-bioenergies.com/inscription-newsletter/ Follow us on LinkedIn Global Bioenergies | NewCap – Investor relations Louis-Victor Delouvrier Aurélie Manavarere globalbioenergies@newcap.eu +33 (0)1 44 71 94 94 NewCap – Media relations Nicolas Merigeau globalbioenergies@newcap.eu +33 (0)1 44 71 94 98 |
1 EBITDA is calculated as operating income plus depreciation, amortisation and provisions and minus reversals of depreciation, amortisation and provisions. It highlights the result generated by the activity without taking into account the entries related to the valuation of the asset.
Attachment
Werbung
Mehr Nachrichten zur Global Bioenergies Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
Andere Nutzer interessierten sich auch für folgende News
07:41 - Mining Investor
